CINXE.COM

<!DOCTYPE html><html lang="en"><head><link rel="stylesheet" data-href="https://fonts.googleapis.com/css?family=Trade+Gothic+Lt+Bold%7COpen+Sans%7CTrade+Gothic+Lt&display=swap" data-optimized-fonts="true"/><title>European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated</title><link rel="icon" href="https://cdn.magloft.com/pwa-664/pwa/logo/8eb186e1-b2cb-4384-a0b7-515f62171b22.png"/><link rel="shortcut icon" type="image/x-icon" href="https://cdn.magloft.com/pwa-664/pwa/logo/8eb186e1-b2cb-4384-a0b7-515f62171b22.png?optimizer=image&format=webp&width=180&aspectRatio=1"/><link rel="apple-touch-icon" sizes="180x180" href="https://cdn.magloft.com/pwa-664/pwa/logo/8eb186e1-b2cb-4384-a0b7-515f62171b22.png?optimizer=image&format=webp&width=180&aspectRatio=1"/><link rel="canonical" href="/domains/www.pharmafocus.com/articles/european-commission-approves-combination-chemotherapy-for-treatm"/><meta name="application-name" content="European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated"/><meta name="apple-mobile-web-app-capable" content="yes"/><meta name="apple-mobile-web-app-status-bar-style" content="default"/><meta name="apple-mobile-web-app-title" content="European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated"/><meta name="format-detection" content="telephone=no"/><meta name="mobile-web-app-capable" content="yes"/><meta name="msapplication-TileColor" content="#1976D2"/><meta name="msapplication-tap-highlight" content="no"/><link rel="manifest" href="/manifest.json"/><meta name="twitter:url" content="https://www.pharmafocus.com"/><meta name="theme-color" content="#1976D2"/><meta name="viewport" content="width=device-width, initial-scale=1"/><meta charSet="utf-8"/><meta itemProp="name" content="European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated"/><meta name="keywords" content="approve"/><meta itemProp="description" content="This month, janssen-cilag international, part of johnson & johnson (j&j) has announced that the european comission (ec) has approved a combined treatment o"/><meta name="description" content="This month, janssen-cilag international, part of johnson & johnson (j&j) has announced that the european comission (ec) has approved a combined treatment o"/><meta itemProp="image" content="https://cdn.magloft.com/pdf-import/1110/images/pages/pg-009.jpg"/><meta property="og:description" content="This month, janssen-cilag international, part of johnson & johnson (j&j) has announced that the european comission (ec) has approved a combined treatment o"/><meta property="og:title" content="European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated"/><meta property="og:site_name" content="European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated"/><meta property="og:image" content="https://cdn.magloft.com/pdf-import/1110/images/pages/pg-009.jpg"/><meta property="og:type" content="website"/><meta name="twitter:card" content="summary_large_image"/><meta name="twitter:title" content="European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated"/><meta name="twitter:description" content="This month, janssen-cilag international, part of johnson & johnson (j&j) has announced that the european comission (ec) has approved a combined treatment o"/><meta name="twitter:image" content="https://cdn.magloft.com/pdf-import/1110/images/pages/pg-009.jpg"/><meta name="author" content="Pharmafocus"/><meta property="article:author" content="Pharmafocus"/><meta property="article:published_time" content="2024-09-05T00:00:00.000Z"/><meta name="twitter:site" content="@Pharmafocus"/><meta name="twitter:creator" content="@Pharmafocus"/><style>html{--heading-font: "Trade Gothic Lt Bold";--body-font: "Open Sans";--ui-font: "Trade Gothic Lt Bold";--top-menu-title-font: "Trade Gothic Lt Bold";--top-menu-subtitle-font: "Trade Gothic Lt";--top-menu-items-font: "Trade Gothic Lt";--footer-menu-title-font: "Trade Gothic Lt Bold";--footer-menu-items-font: "Trade Gothic Lt Bold";--background-color: #FFFFFF;--background-color-dark: #808080;--primary-color: #1976D2;--primary-color-dark: #0C3B69;--secondary-color: #795FF4;--secondary-color-dark: #250B9F;--accent-color: #D76FD6;--accent-color-dark: #80237F;--info-color: #41638C;--info-color-dark: #213246;--warning-color: #EF9338;--warning-color-dark: #89490B;--success-color: #20AD27;--success-color-dark: #105714;--danger-color: #DF4241;--danger-color-dark: #7B1515;--top-menu-background-color: #EE1C25;--top-menu-background-color-dark: #7C090E;--footer-menu-background-color: #DF1111;--footer-menu-background-color-dark: #6F0808;--navbar-height: 64px; }</style><link rel="stylesheet" href="https://cdn.magloft.com/reader/fonts/trade-gothic-lt.css"/><link rel="stylesheet" href="https://cdn.magloft.com/reader/fonts/trade-gothic-lt-bold.css"/><script type="text/javascript" src="https://cdn.jsdelivr.net/npm/cookie-bar/cookiebar-latest.min.js?customize=1&always=1&showNoConsent=1"></script><meta name="google-site-verification" content="kuOvGxaH_NjG3aS7GSmbjjV-OjdOAWyiM3gEPGESeHQ"/><style> #billboard-banner { text-align:center;} #billboard-banner img {min-width:728px; max-width:970px; height:auto; position:relative; top:70px;} .Layout_spacer__qTBD3 {margin-top:70px;} </style><meta name="next-head-count" content="44"/><link rel="preconnect" href="https://fonts.googleapis.com"/><link rel="preconnect" href="https://fonts.gstatic.com"/><link rel="preload" href="/_next/static/css/b1dcce53b81730b3.css" as="style"/><link rel="stylesheet" href="/_next/static/css/b1dcce53b81730b3.css" data-n-g=""/><link rel="preload" href="/_next/static/css/f55b13f5723aaa37.css" as="style"/><link rel="stylesheet" href="/_next/static/css/f55b13f5723aaa37.css" data-n-p=""/><link rel="preload" href="/_next/static/css/b8b2c08e66691c64.css" as="style"/><link rel="stylesheet" href="/_next/static/css/b8b2c08e66691c64.css" data-n-p=""/><noscript data-n-css=""></noscript><script defer="" nomodule="" src="/_next/static/chunks/polyfills-c67a75d1b6f99dc8.js"></script><script defer="" src="https://fonts.googleapis.com/css?family=Open+Sans&display=swap" data-nscript="beforeInteractive"></script><script src="/_next/static/chunks/webpack-8c0406b9161964c2.js" defer=""></script><script src="/_next/static/chunks/framework-73b8966a3c579ab0.js" defer=""></script><script src="/_next/static/chunks/main-34cb81d5753e1fc4.js" defer=""></script><script src="/_next/static/chunks/pages/_app-8fa6eb38aaba2acc.js" defer=""></script><script src="/_next/static/chunks/ad273671-3092333ffa02af02.js" defer=""></script><script src="/_next/static/chunks/876-c944523f292a2885.js" defer=""></script><script src="/_next/static/chunks/223-fe6833f316a5a95f.js" defer=""></script><script src="/_next/static/chunks/702-907e0a115a4d5f32.js" defer=""></script><script src="/_next/static/chunks/174-170bbdbd822e7a4f.js" defer=""></script><script src="/_next/static/chunks/651-580f7aec9fa2a9c7.js" defer=""></script><script src="/_next/static/chunks/998-4c6a5fcdba301010.js" defer=""></script><script src="/_next/static/chunks/pages/domains/%5Bdomain%5D/articles/%5Bslug%5D-8d929c887d4161d3.js" defer=""></script><script src="/_next/static/Kev2Q3R5ZPSsq42hjt5aX/_buildManifest.js" defer=""></script><script src="/_next/static/Kev2Q3R5ZPSsq42hjt5aX/_ssgManifest.js" defer=""></script><style data-styled="" data-styled-version="5.3.9"></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Trade+Gothic+Lt+Bold%7COpen+Sans%7CTrade+Gothic+Lt&display=swap"/></head><body><div id="__next"><div class="Layout_container__gktH6"><div class="Layout_navbar-container__gCfDZ" style="height:64px"><nav class="_wrapper_jbnbd_1"><div class="_container_jbnbd_15"><div class="_navbar-prefix_jbnbd_108"><div class="Layout_prefix__7W2Vq"><button><div class="_nav-arrow-left_1lm7t_183 _icon_1lm7t_1 icon"></div></button></div></div><a class="_navbar-brand_jbnbd_29" aria-label="Pharmafocus" href="/"><div class="_navbar-image_jbnbd_40"><img alt="Logo" loading="lazy" decoding="async" data-nimg="fill" class="_image_jbnbd_43" style="position:absolute;height:100%;width:100%;left:0;top:0;right:0;bottom:0;color:transparent" sizes="100vw" srcSet="https://media.magloft.app/pwa-664/pwa/top-menu-icon/c215ba48-44be-411d-8753-7438a6acf8fb.png 54w, https://media.magloft.app/pwa-664/pwa/top-menu-icon/c215ba48-44be-411d-8753-7438a6acf8fb.png 70w, https://media.magloft.app/pwa-664/pwa/top-menu-icon/c215ba48-44be-411d-8753-7438a6acf8fb.png 82w, https://media.magloft.app/pwa-664/pwa/top-menu-icon/c215ba48-44be-411d-8753-7438a6acf8fb.png 96w, https://media.magloft.app/pwa-664/pwa/top-menu-icon/c215ba48-44be-411d-8753-7438a6acf8fb.png 110w, https://media.magloft.app/pwa-664/pwa/top-menu-icon/c215ba48-44be-411d-8753-7438a6acf8fb.png 128w, https://media.magloft.app/pwa-664/pwa/top-menu-icon/c215ba48-44be-411d-8753-7438a6acf8fb.png 138w, https://media.magloft.app/pwa-664/pwa/top-menu-icon/c215ba48-44be-411d-8753-7438a6acf8fb.png 192w, https://media.magloft.app/pwa-664/pwa/top-menu-icon/c215ba48-44be-411d-8753-7438a6acf8fb.png 200w, https://media.magloft.app/pwa-664/pwa/top-menu-icon/c215ba48-44be-411d-8753-7438a6acf8fb.png 252w, https://media.magloft.app/pwa-664/pwa/top-menu-icon/c215ba48-44be-411d-8753-7438a6acf8fb.png 260w, https://media.magloft.app/pwa-664/pwa/top-menu-icon/c215ba48-44be-411d-8753-7438a6acf8fb.png 298w, https://media.magloft.app/pwa-664/pwa/top-menu-icon/c215ba48-44be-411d-8753-7438a6acf8fb.png 378w, https://media.magloft.app/pwa-664/pwa/top-menu-icon/c215ba48-44be-411d-8753-7438a6acf8fb.png 384w, https://media.magloft.app/pwa-664/pwa/top-menu-icon/c215ba48-44be-411d-8753-7438a6acf8fb.png 520w, https://media.magloft.app/pwa-664/pwa/top-menu-icon/c215ba48-44be-411d-8753-7438a6acf8fb.png 640w, https://media.magloft.app/pwa-664/pwa/top-menu-icon/c215ba48-44be-411d-8753-7438a6acf8fb.png 756w, https://media.magloft.app/pwa-664/pwa/top-menu-icon/c215ba48-44be-411d-8753-7438a6acf8fb.png 828w, https://media.magloft.app/pwa-664/pwa/top-menu-icon/c215ba48-44be-411d-8753-7438a6acf8fb.png 1080w, https://media.magloft.app/pwa-664/pwa/top-menu-icon/c215ba48-44be-411d-8753-7438a6acf8fb.png 1200w, https://media.magloft.app/pwa-664/pwa/top-menu-icon/c215ba48-44be-411d-8753-7438a6acf8fb.png 1920w, https://media.magloft.app/pwa-664/pwa/top-menu-icon/c215ba48-44be-411d-8753-7438a6acf8fb.png 2048w" src="https://media.magloft.app/pwa-664/pwa/top-menu-icon/c215ba48-44be-411d-8753-7438a6acf8fb.png"/></div><div class="_navbar-title_jbnbd_58 _navbar-title-hide_jbnbd_101"></div></a><div id="navbar-children-container" class="_navbar-children_jbnbd_116"><div class="_menu_1jhrl_1"><div class="_menu-wrapper_1jhrl_22"><div class="_menu-items_1jhrl_38"><a class="_menu-item_1jhrl_38" href="/"><div class="_menu-home_1lm7t_255 _menu-item-icon_1jhrl_97 _icon_1lm7t_1 icon"></div><div class="_menu-item-title_1jhrl_88">Home</div><div class="_indicator_1jhrl_63"></div></a><a class="_menu-item_1jhrl_38 _active_1jhrl_70" href="/articles"><div class="_menu-articles_1lm7t_259 _menu-item-icon_1jhrl_97 _icon_1lm7t_1 icon"></div><div class="_menu-item-title_1jhrl_88">Articles</div><div class="_indicator_1jhrl_63 _active_1jhrl_70"></div></a><a class="_menu-item_1jhrl_38" href="/collections"><div class="_menu-issues_1lm7t_263 _menu-item-icon_1jhrl_97 _icon_1lm7t_1 icon"></div><div class="_menu-item-title_1jhrl_88">Magazines</div><div class="_indicator_1jhrl_63"></div></a><a class="_menu-item_1jhrl_38" href="/account/login"><div class="_menu-account_1lm7t_411 _menu-item-icon_1jhrl_97 _icon_1lm7t_1 icon"></div><div class="_menu-item-title_1jhrl_88">Log in</div><div class="_indicator_1jhrl_63"></div></a></div></div></div></div><div id="navbar-suffix" class="_navbar-suffix_jbnbd_108"><div class="Layout_menu-actions__vsDbI"><div class="Layout_install-button__FBfSr"><div class="Tooltip_tooltip__98Sw9"></div><button class="_button_19h3g_1 _text_19h3g_12 _medium_19h3g_38 _secondary_19h3g_22" type="button" style="color:var(--top-menu-item-icon-color, var(--background-color))" role="button" aria-label="Search" aria-labelledby="labeldiv" title="Search"><div class="_action-search_1lm7t_15 _icon-button_19h3g_19 _icon_1lm7t_1 icon" style="background-color:var(--top-menu-item-icon-color, var(--background-color))"></div></button></div></div></div></div></nav></div><div class="Layout_main__evUHx"><div class="Layout_spacer__qTBD3" style="height:64px"></div><div class="_slug__container__7sxKh"><div class=""></div><div class=""><div id="print-article" class="_slug__article__BPEHu"><div class="Article-module_article__kO4b9"><div id="outer" data-widget="page-widget" style="background-color:#FFFFFF;padding:16px 0px 24px 0px;color:#000000;text-align:left;font-family:"Open Sans"" class="Widget-module_outer__PBh8P Page-module_outer__g0XXH"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 0px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>Approvals</p></div></div><div id="outer" data-widget="horizontal-rule-widget" style="background-color:transparent;padding:0px 24px 0px 24px" class="Widget-module_outer__PBh8P HorizontalRule-module_outer__3UqSE"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><hr style="border-top-style:solid;border-top-width:3px;border-top-color:#a31f29"/></div></div><div id="outer" data-widget="heading-widget" style="background-color:transparent;padding:0px 24px 16px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Heading-module_container__uHf-4"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><h2><span style="font-family:"Roboto Slab"" class="__bold">European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients</span></h2></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__bold" style="color:rgb(38,37,35)">This month, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission (EC) has approved a combined treatment of rybrevant (amivantamab) and chemotherapy (carboplatin and pemerexed) for the treatment of non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR). </span></p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>John Reed, MD PhD, executive vice president, Innovative Medicine, R&D, Johnson & Johnson commented “Today’s FDA approval of chemotherapy-free rybrevant plus lazcluze in the first line is an incredible step towards our goal of altering the trajectory of lung cancer and reducing the impact of the world’s leading cause of cancer mortality.”</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>The decision comes after the results of the phase 3 MARIPOSA study were announced. The study evaluated the safety profile and to the efficacy of amivantamab and chemotherapy in patients with locally-advanced or metastatic EGFR ex19del or L858R substitution NSCLC who had disease progression on or after treatment with osimertinib.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>Antonio Passaro, MD PhD, medical oncologist, Division of Thoracic Oncology at the European Institute of Oncology in Milan, Italy stated: “The addition of the bispecific antibody amivantamab to chemotherapy offers an important new treatment option for patients with EGFR ex19del or L858R mutations, progressing on or after osimertinib. In this setting, this combination set the new landmark for overall response rate and reduced the risk of disease progression or death by more than half compared to standard chemotherapy alone. It also demonstrated significant improvements in intracranial progression-free survival.”</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>The trial met its primary endpoint, reducing the risk of disease progression or death by a significant 52% in comparison to chemotherapy alone. Additionally, amivantamab plus chemotherapy showed an objective response rate (ORR) of 64%, compared to 36 % with chemotherapy alone.</p></div></div></div></div></div><div class="_slug__share-button__ettip"><hr/></div></div></div><div id="ControlBar" class="_slug__control-bar__Jj4LE"><div class="WrapAutoHide-module_navigation__9sdQy WrapAutoHide-module_visible__UN7GD"><div class="ControlBar-module_toc-wrapper__AF5eD"><div class="ControlBar-module_toc__mKXnp"><div class="ControlBar-module_white-blur__TGapK"><div class="ControlBar-module_toc-slider__i9fv1"></div></div><div class="ControlBar-module_control-bar__9Zqak"><button class=""><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none"><path d="M13.8287 19C13.5367 19 13.2467 18.873 13.0487 18.627L8.22066 12.627C7.92266 12.256 7.92666 11.726 8.23166 11.36L13.2317 5.35998C13.5847 4.93598 14.2157 4.87898 14.6407 5.23198C15.0647 5.58498 15.1217 6.21598 14.7677 6.63998L10.2927 12.011L14.6077 17.373C14.9537 17.803 14.8857 18.433 14.4547 18.779C14.2707 18.928 14.0487 19 13.8287 19Z" fill="white"></path></svg></button><button class=""><svg width="20" height="20" viewBox="0 0 20 20" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M5 8C4.80222 8 4.60888 8.05865 4.44443 8.16853C4.27998 8.27841 4.15181 8.43459 4.07612 8.61732C4.00043 8.80004 3.98063 9.00111 4.01921 9.19509C4.0578 9.38907 4.15304 9.56725 4.29289 9.70711C4.43275 9.84696 4.61093 9.9422 4.80491 9.98079C4.99889 10.0194 5.19996 9.99957 5.38268 9.92388C5.56541 9.84819 5.72159 9.72002 5.83147 9.55557C5.94135 9.39112 6 9.19778 6 9C6 8.73478 5.89464 8.48043 5.70711 8.29289C5.51957 8.10536 5.26522 8 5 8ZM17 4H16V1C16 0.734784 15.8946 0.48043 15.7071 0.292893C15.5196 0.105357 15.2652 0 15 0H5C4.73478 0 4.48043 0.105357 4.29289 0.292893C4.10536 0.48043 4 0.734784 4 1V4H3C2.20435 4 1.44129 4.31607 0.87868 4.87868C0.316071 5.44129 0 6.20435 0 7V13C0 13.7956 0.316071 14.5587 0.87868 15.1213C1.44129 15.6839 2.20435 16 3 16H4V19C4 19.2652 4.10536 19.5196 4.29289 19.7071C4.48043 19.8946 4.73478 20 5 20H15C15.2652 20 15.5196 19.8946 15.7071 19.7071C15.8946 19.5196 16 19.2652 16 19V16H17C17.7956 16 18.5587 15.6839 19.1213 15.1213C19.6839 14.5587 20 13.7956 20 13V7C20 6.20435 19.6839 5.44129 19.1213 4.87868C18.5587 4.31607 17.7956 4 17 4ZM6 2H14V4H6V2ZM14 18H6V14H14V18ZM18 13C18 13.2652 17.8946 13.5196 17.7071 13.7071C17.5196 13.8946 17.2652 14 17 14H16V13C16 12.7348 15.8946 12.4804 15.7071 12.2929C15.5196 12.1054 15.2652 12 15 12H5C4.73478 12 4.48043 12.1054 4.29289 12.2929C4.10536 12.4804 4 12.7348 4 13V14H3C2.73478 14 2.48043 13.8946 2.29289 13.7071C2.10536 13.5196 2 13.2652 2 13V7C2 6.73478 2.10536 6.48043 2.29289 6.29289C2.48043 6.10536 2.73478 6 3 6H17C17.2652 6 17.5196 6.10536 17.7071 6.29289C17.8946 6.48043 18 6.73478 18 7V13Z" fill="white"></path></svg></button><button class=""><svg xmlns="http://www.w3.org/2000/svg" width="18" height="14" viewBox="0 0 18 14" fill="none"><path d="M6.75 0H1.125C0.503719 0 0 0.503719 0 1.125V4.5C0 5.12128 0.503719 5.625 1.125 5.625C1.74628 5.625 2.25 5.12128 2.25 4.5V2.25H6.75C7.37128 2.25 7.875 1.74628 7.875 1.125C7.875 0.503719 7.37128 0 6.75 0Z" fill="white"></path><path d="M16.875 0H11.25C10.6287 0 10.125 0.503719 10.125 1.125C10.125 1.74628 10.6287 2.25 11.25 2.25H15.75V4.5C15.75 5.12128 16.2537 5.625 16.875 5.625C17.4963 5.625 18 5.12128 18 4.5V1.125C18 0.503719 17.4963 0 16.875 0Z" fill="white"></path><path d="M16.875 7.875C16.2537 7.875 15.75 8.37872 15.75 9V11.25H11.25C10.6287 11.25 10.125 11.7537 10.125 12.375C10.125 12.9963 10.6287 13.5 11.25 13.5H16.875C17.4963 13.5 18 12.9963 18 12.375V9C18 8.37872 17.4963 7.875 16.875 7.875Z" fill="white"></path><path d="M6.75 11.25H2.25V9C2.25 8.37872 1.74628 7.875 1.125 7.875C0.503719 7.875 0 8.37872 0 9V12.375C0 12.9963 0.503719 13.5 1.125 13.5H6.75C7.37128 13.5 7.875 12.9963 7.875 12.375C7.875 11.7537 7.37128 11.25 6.75 11.25Z" fill="white"></path></svg></button><button class="" disabled=""><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none"><g opacity="0.25"><path d="M9.9995 19C9.7735 19 9.5465 18.924 9.3595 18.768C8.9355 18.415 8.8785 17.784 9.2315 17.36L13.7075 11.989L9.3925 6.62701C9.0465 6.19701 9.1145 5.56701 9.5445 5.22101C9.9755 4.87501 10.6045 4.94301 10.9515 5.37301L15.7795 11.373C16.0775 11.744 16.0735 12.274 15.7685 12.64L10.7685 18.64C10.5705 18.877 10.2865 19 9.9995 19Z" fill="white"></path></g></svg></button></div></div></div></div></div><div class="_slug__wrapper__0ZIJf"></div><div></div>0</div></div><script> //create a new element const terms = document.createElement('div'); //set id terms.setAttribute("id","billboard-banner"); //add the new element to html var body = document.querySelector('body'); body.appendChild(terms); document.querySelector("#billboard-banner").innerHTML = "<ins data-revive-zoneid='1573' data-revive-id='9c421b7e485bf2edfee09708a4d06e2e'></ins>"; //insert new element before header //document.body.insertAdjacentElement('afterbegin', terms); const insElement = document.querySelector("#__next"); insElement.before(terms); </script> <script async="" src="//ads.datateam.co.uk/www/delivery/asyncjs.php"></script><div class="_footer_j8nu5_1"><div class="_container_j8nu5_12"><div class="_footer-row_j8nu5_23"><div class="_footer-column_j8nu5_36 _flex-2_j8nu5_117"><div class="_footer-brand_j8nu5_43"><div class=""><img alt="Logo" loading="lazy" width="40" height="40" decoding="async" data-nimg="1" class="_footer-logo_j8nu5_57" style="color:transparent" srcSet="https://media.magloft.app/pwa-664/pwa/logo/8eb186e1-b2cb-4384-a0b7-515f62171b22.png 1x, https://media.magloft.app/pwa-664/pwa/logo/8eb186e1-b2cb-4384-a0b7-515f62171b22.png 2x" src="https://media.magloft.app/pwa-664/pwa/logo/8eb186e1-b2cb-4384-a0b7-515f62171b22.png"/></div><div class="_content_j8nu5_67"><h3>Pharmafocus</h3><p>Pharmaceutical Industry news, analysis and insights</p></div></div><div class="_footer-link-list_j8nu5_121"><div class="_block_j8nu5_129"><a class="_footer-link-item_j8nu5_92" rel="noreferrer" href="mailto:info@pharmafile.com"><div class="_form-email_1lm7t_143 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span>info@pharmafile.com</span></a></div><div class="_block_j8nu5_129"><a class="_footer-link-item_j8nu5_92" target="_blank" rel="noreferrer" href="http://www.pharmafile.com"><div class="_status-info_1lm7t_87 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span>Pharmafile.com</span></a><a class="_footer-link-item_j8nu5_92" target="_blank" rel="noreferrer" href="https://magazine.pharmafile.com"><div class="_status-info_1lm7t_87 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span>Pharmafile Magazine</span></a><a class="_footer-link-item_j8nu5_92" target="_blank" rel="noreferrer" href="http://www.samedanltd.com"><div class="_status-info_1lm7t_87 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span>Samedan</span></a></div><a target="_blank" rel="noreferrer" class="_footer-link-item_j8nu5_92" href="https://www.pharmafile.com/privacy-policy"><div class="_status-info_1lm7t_87 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span>Privacy Policy</span></a><a target="_blank" rel="noreferrer" class="_footer-link-item_j8nu5_92" href="https://www.pharmafile.com/terms-of-service"><div class="_status-info_1lm7t_87 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span>Terms of Service</span></a></div></div><div class="_footer-column_j8nu5_36 _flex-1_j8nu5_39"><div class="_footer-brand_j8nu5_43"><div class="_status-accent_1lm7t_91 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><div class="_content_j8nu5_67"><h3>Categories</h3><p>Explore our inspiring content by topic</p></div></div><div class="_footer-link-list_j8nu5_121"><a class="_footer-link-item_j8nu5_92" href="/categories/uk-pharma-news"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>UK News</a><a class="_footer-link-item_j8nu5_92" href="/categories/general-news"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>General News</a><a class="_footer-link-item_j8nu5_92" href="/categories/approvals"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Approvals</a><a class="_footer-link-item_j8nu5_92" href="/categories/research-and-development"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>R & D</a><a class="_footer-link-item_j8nu5_92" href="/categories/mergers-acquisitions"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Mergers & Acquisitions</a><a class="_footer-link-item_j8nu5_92" href="/categories/manufacturing-production"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Manufacturing</a><a class="_footer-link-item_j8nu5_92" href="/categories/clinical-trials"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Clinical Trials</a><a class="_footer-link-item_j8nu5_92" href="/categories/industry-insights"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Industry Insights</a><a class="_footer-link-item_j8nu5_92" href="/categories/appointments"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Appointments</a><a class="_footer-link-item_j8nu5_92" href="/categories/insider-interviews"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Interviews</a></div></div><div class="_footer-column_j8nu5_36 _flex-1_j8nu5_39"><div class="_footer-brand_j8nu5_43"><div class="_share-action_1lm7t_463 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><div class="_content_j8nu5_67"><h3>Social Footprints</h3><p>Follow us on our Social Media Channels</p></div></div><div class="_footer-link-list_j8nu5_121"><a class="_footer-link-item_j8nu5_92" target="_blank" rel="noreferrer" href="https://twitter.com/Pharmafocus"><div class="_share-twitter_1lm7t_487 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span class="_footer-text_j8nu5_125">X</span></a><a class="_footer-link-item_j8nu5_92" target="_blank" rel="noreferrer" href="https://www.linkedin.com/company/pharmafile"><div class="_share-linkedin_1lm7t_483 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span class="_footer-text_j8nu5_125">linkedin</span></a></div></div></div></div></div></div><div class="Toastify"></div></div><script id="__NEXT_DATA__" type="application/json">{"props":{"pageProps":{"domain":"www.pharmafocus.com","pwa":{"id":664,"publicationId":14882,"pwaOptinId":656,"domain":"www.pharmafocus.com","config":{"access":{"concurrentLimit":null,"restrictAnonymous":null,"disableSignup":null,"disableLogin":null,"disableLoginMessage":null,"disableSearchIndexing":false,"signupUrl":null,"resetPasswordUrl":null,"isUsernameLogin":null,"disableEditProfile":null,"formUrl":null,"customMarginResetPassword":null},"push":{"google":{"serverPublicKey":"BGfKWie38SRvrZs4-bDa1N70rhULMBqX8nAvBZT_2OXsMQi3uRA0CaK4JKPuib9Ega28liCTGhBx0QCY4t1QU7o"}},"tracking":{"facebook":{"appId":null,"pixelId":null},"google":{"measurementId":"G-D8QLP3CKWG"},"gtm":null,"sentry":true},"payment":{"stripe":null,"bypassPayment":null,"mode":"none","external":null,"currency":null},"email":{"readerOptin":false},"firebase":{"projectId":"ipt-magloft","senderId":"497261264876","pairKey":null,"webAppConfig":{"apiKey":"AIzaSyBcHBC8k394YdXp19dZj2Xqe8CXCgThBZs","appId":"1:497261264876:web:98452398b320341bd68ac9","authDomain":"ipt-magloft.firebaseapp.com","databaseURL":null,"locationId":null,"messagingSenderId":"497261264876","projectId":"ipt-magloft","storageBucket":"ipt-magloft.appspot.com"}},"customHtml":{"head":"\u003cscript type=\"text/javascript\" src=\"https://cdn.jsdelivr.net/npm/cookie-bar/cookiebar-latest.min.js?customize=1\u0026always=1\u0026showNoConsent=1\" onload=\"setupCookieBar();\"\u003e\u003c/script\u003e\n\u003cmeta name=\"google-site-verification\" content=\"kuOvGxaH_NjG3aS7GSmbjjV-OjdOAWyiM3gEPGESeHQ\" /\u003e\n\u003cstyle\u003e\n#billboard-banner { text-align:center;}\n#billboard-banner img {min-width:728px; max-width:970px; height:auto; position:relative; top:70px;}\n.Layout_spacer__qTBD3 {margin-top:70px;}\n\u003c/style\u003e","body":"\u003cscript\u003e\n //create a new element\n const terms = document.createElement('div');\n //set id\n terms.setAttribute(\"id\",\"billboard-banner\");\n //add the new element to html\n var body = document.querySelector('body');\n body.appendChild(terms);\n document.querySelector(\"#billboard-banner\").innerHTML = \"\u003cins data-revive-zoneid='1573' data-revive-id='9c421b7e485bf2edfee09708a4d06e2e'\u003e\u003c/ins\u003e\"; \n //insert new element before header\n//document.body.insertAdjacentElement('afterbegin', terms);\n const insElement = document.querySelector(\"#__next\");\n insElement.before(terms);\n\u003c/script\u003e\n\u003cscript async src=\"//ads.datateam.co.uk/www/delivery/asyncjs.php\"\u003e\u003c/script\u003e"},"account":{"emailEditable":true,"customSubscriptionText":null,"customSubscriptionURL":null,"enableSubscriptionTitle":null},"checkout":null,"tts":{"enabled":true,"voice":"alloy","color":"#EBEBEB","backgroundColor":"#226BA0"},"customFields":null},"design":{"colors":{"backgroundColor":"#FFFFFF","primaryColor":"#1976D2","secondaryColor":"#795FF4","accentColor":"#D76FD6","infoColor":"#41638C","warningColor":"#EF9338","successColor":"#20AD27","dangerColor":"#DF4241","topMenuBackgroundColor":"#EE1C25","topMenuHeadingTitleColor":null,"topMenuHeadingIconColor":null,"topMenuItemTextColor":null,"topMenuItemIconColor":null,"footerMenuBackgroundColor":"#DF1111","footerMenuHeadingTitleColor":null,"footerMenuHeadingTextColor":null,"footerMenuHeadingIconColor":null,"footerMenuItemTextColor":null,"footerMenuItemIconColor":null},"images":{"icon":"https://cdn.magloft.com/pwa-664/pwa/logo/8eb186e1-b2cb-4384-a0b7-515f62171b22.png","feature":"https://cdn.magloft.com/defaults/feature-graphic.jpg","topMenuIcon":"https://cdn.magloft.com/pwa-664/pwa/top-menu-icon/c215ba48-44be-411d-8753-7438a6acf8fb.png","footerMenuIcon":null,"alphaChannelIcon":null},"fonts":{"heading":"trade-gothic-lt-bold","body":"open-sans","ui":"trade-gothic-lt-bold","topMenuTitle":"trade-gothic-lt-bold","topMenuItems":"trade-gothic-lt","topMenuSubtitle":"trade-gothic-lt","footerMenuTitle":null,"footerMenuItems":null},"menuItems":{"collections":{"title":"Magazines"},"articles":{"title":null},"account":{"title":null},"icons":{"enabled":true}},"footerShape":"flat","issueCoverAspectRatio":0.75,"fullscreenCollectionView":"auto","customOverlayToggleView":false,"defaultViewMode":"html","categories":"flat","purchaseList":true,"libraryList":false,"enablePrint":true,"noteList":false,"textToSpeech":false,"issue":{"dateHidden":null,"categoryHidden":null},"filter":{"enableSearch":null}},"layout":{"banners":[{"image":"https://cdn.magloft.com/pwa-1/pwa/banner/aea74608-e04a-4649-b817-c45cc439e28e.png","title":"Start trial now","isHidden":true,"action":{"type":"url","href":"https://www.magloft.com/","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}}],"bottomBanners":[{"image":"https://cdn.magloft.com/pwa-664/pwa/banner/1f66e6ea-9b3a-4477-aba1-18abf54619b8.png","title":null,"isHidden":true,"action":{"type":"url","href":"http://www.samedanltd.com/","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}}],"columnSeparator":"shadow","tabs":[{"route":"","title":"Home","icon":"menu-home","visible":true},{"route":"/articles","title":"Articles","icon":"menu-articles","visible":true},{"route":"/collections","title":"Collections","icon":"menu-issues","visible":true},{"route":"/account","title":"Account","icon":"menu-account","visible":true}],"topMenu":{"showLogo":true,"showSubtitle":false,"showTitle":false,"height":"64px"},"navbar":{"animation":false,"style":"logo-left"},"sections":[{"fullWidth":true,"backgroundColor":"transparent","columnSeparator":"none","columns":[{"size":5,"blocks":[{"type":"banner","image":"https://cdn.magloft.com/pwa-1/pwa/banner/aea74608-e04a-4649-b817-c45cc439e28e.png","isHidden":true,"title":"Start trial now","action":{"type":"url","href":"https://www.magloft.com/","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}}]}]},{"fullWidth":false,"backgroundColor":null,"columnSeparator":"shadow","columns":[{"size":8.5,"blocks":[{"type":"ad","title":"Advertisement","advertisementIds":[],"adCampaignId":892,"condition":null},{"type":"article-list","condition":null,"color":"#F90505","title":"Top Content","variant":"variant-b","articleIds":[271022,271018,271015,270997,262748,270996],"articles":null},{"type":"article-list","condition":null,"color":"#2873B0","title":"Industry Insights","variant":"variant-b","articleIds":[271022,260492,260493,260494,258746,258745,257361],"articles":null},{"type":"article-category","condition":null,"color":"#F90505","title":"Mergers \u0026 Acquisitions","variant":"variant-c","categoryId":43143,"backgroundColor":null,"image":null,"articles":null,"category":null},{"type":"article-category","condition":null,"color":"#2873B0","title":"Approvals","variant":"variant-c","categoryId":43140,"backgroundColor":null,"image":null,"articles":null,"category":null},{"type":"article-category","condition":null,"color":"#2873B0","title":"General News","variant":"variant-c","categoryId":43139,"backgroundColor":null,"image":null,"articles":null,"category":null},{"type":"guide-install","color":"#444558","title":"How to Install","condition":null}]},{"size":3.5,"blocks":[{"type":"issue-slider","condition":null,"color":"#2873B0","title":"Latest Editions","issueIds":[527273,526915,52826,52799,52483,52217,51921,51722,51533,51435,51240,51075,45938,45939,45940],"thumbnail":{"style":"full-cover","size":"medium"},"borderRadius":null,"zoomOnHover":true,"issues":null},{"type":"ad","title":"Advertisement","advertisementIds":[2210],"adCampaignId":null,"condition":null},{"type":"cta","condition":null,"icon":"symbol-gift","color":"#FB0505","title":"Newsletters","description":"Sign up to our newsletters and digital magazines","action":{"type":"url","href":"https://curwoodcmsltd.formstack.com/forms/samedan","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}},{"type":"ad","title":"Advertisement","advertisementIds":[2067],"adCampaignId":null,"condition":null},{"type":"cta","condition":null,"icon":"symbol-day","color":"#F90505","title":"Pharmafocus Archive","description":"Browse older editions","action":{"type":"url","href":"https://en.calameo.com/subscriptions/6188508","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}},{"type":"ad","title":"Advertisement","advertisementIds":[],"adCampaignId":1044,"condition":null},{"type":"article-category","condition":null,"color":"#F70707","title":"Appointments","variant":"variant-c","categoryId":43146,"backgroundColor":null,"image":null,"articles":null,"category":null}]}]},{"fullWidth":true,"backgroundColor":"transparent","columnSeparator":"none","columns":[{"size":5,"blocks":[{"type":"banner","image":"https://cdn.magloft.com/pwa-664/pwa/banner/1f66e6ea-9b3a-4477-aba1-18abf54619b8.png","isHidden":true,"title":"","action":{"type":"url","href":"http://www.samedanltd.com/","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}}]}]}],"columns":[{"size":8.5,"blocks":[{"type":"ad","title":"Advertisement","advertisementIds":[],"adCampaignId":892,"condition":null},{"type":"article-list","condition":null,"color":"#F90505","title":"Top Content","variant":"variant-b","articleIds":[271022,271018,271015,270997,262748,270996],"articles":null},{"type":"article-list","condition":null,"color":"#2873B0","title":"Industry Insights","variant":"variant-b","articleIds":[271022,260492,260493,260494,258746,258745,257361],"articles":null},{"type":"article-category","condition":null,"color":"#F90505","title":"Mergers \u0026 Acquisitions","variant":"variant-c","categoryId":43143,"backgroundColor":null,"image":null,"articles":null,"category":null},{"type":"article-category","condition":null,"color":"#2873B0","title":"Approvals","variant":"variant-c","categoryId":43140,"backgroundColor":null,"image":null,"articles":null,"category":null},{"type":"article-category","condition":null,"color":"#2873B0","title":"General News","variant":"variant-c","categoryId":43139,"backgroundColor":null,"image":null,"articles":null,"category":null},{"type":"guide-install","color":"#444558","title":"How to Install","condition":null}]},{"size":3.5,"blocks":[{"type":"issue-slider","condition":null,"color":"#2873B0","title":"Latest Editions","issueIds":[527273,526915,52826,52799,52483,52217,51921,51722,51533,51435,51240,51075,45938,45939,45940],"thumbnail":{"style":"full-cover","size":"medium"},"borderRadius":null,"zoomOnHover":true,"issues":null},{"type":"ad","title":"Advertisement","advertisementIds":[2210],"adCampaignId":null,"condition":null},{"type":"cta","condition":null,"icon":"symbol-gift","color":"#FB0505","title":"Newsletters","description":"Sign up to our newsletters and digital magazines","action":{"type":"url","href":"https://curwoodcmsltd.formstack.com/forms/samedan","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}},{"type":"ad","title":"Advertisement","advertisementIds":[2067],"adCampaignId":null,"condition":null},{"type":"cta","condition":null,"icon":"symbol-day","color":"#F90505","title":"Pharmafocus Archive","description":"Browse older editions","action":{"type":"url","href":"https://en.calameo.com/subscriptions/6188508","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}},{"type":"ad","title":"Advertisement","advertisementIds":[],"adCampaignId":1044,"condition":null},{"type":"article-category","condition":null,"color":"#F70707","title":"Appointments","variant":"variant-c","categoryId":43146,"backgroundColor":null,"image":null,"articles":null,"category":null}]}]},"seo":{"home":{"title":"Pharmafocus Magazine - covering pharma and biotech since 1986","description":"Reporting on the pharma industry, drug development \u0026 clinical trials, manufacturing, logistics, market access, and patients.\nFrom breaking stories to interviews with senior executives, we look at regulations \u0026 trends to provide useful market intelligence.","image":"https://cdn.magloft.com/pwa-664/seo/image/270800d8-b1de-41b8-86ad-5d262d2b9adf.png","imageAlt":"Pharmafocus Magazine"},"articles":{"title":"Pharmafocus - Articles","description":"Discover the latest articles published by Pharmafocus. Browse and customize the article feed to your preferences and explore latest trends","image":"https://cdn.magloft.com/pwa-664/seo/image/e7a95017-d617-4914-b4b3-09fcfc683f75.png","imageAlt":"Pharmafocus - Articles"},"issues":{"title":"Pharmafocus - Magazine Issues","description":"Explore the latest issues of Pharmafocus Magazine and keep up to date with the latest industry knowledge","image":"https://cdn.magloft.com/pwa-664/seo/image/b1c374f3-b368-4654-bf00-3b5ed81fe6c2.png","imageAlt":"Pharmafocus - Issues"},"account":{"title":"Pharmafocus - Account","description":"Manage your Pharmafocus Reader Account..","image":"https://cdn.magloft.com/pwa-664/seo/image/5ad881b1-a927-4fb1-b331-81963e9a0f84.png","imageAlt":"Reader Account"}},"strings":{"app":{"title":"Pharmafocus","subtitle":"Pharmaceutical Industry news, analysis and insights"},"social":{"facebook":null,"twitter":"https://twitter.com/Pharmafocus","linkedin":"https://www.linkedin.com/company/pharmafile","youtube":null,"instagram":null},"topMenu":{"title":null,"subtitle":null},"footerMenu":{"title":"Pharmafocus","subtitle":null,"description":null,"email":["info@pharmafile.com"],"privacyUrl":"https://www.pharmafile.com/privacy-policy","termsUrl":"https://www.pharmafile.com/terms-of-service","links":[{"name":"Pharmafile.com","url":"http://www.pharmafile.com"},{"name":"Pharmafile Magazine","url":"https://magazine.pharmafile.com"},{"name":"Samedan","url":"http://www.samedanltd.com"}]},"pages":null},"customFonts":[{"identifier":"trade-gothic-lt"},{"identifier":"trade-gothic-lt-bold"}],"phrases":{},"trialEndAt":null,"bypassSubscription":false},"publication":{"id":14882,"title":"Pharmafocus","properties":{"subtitle":null,"appIcon":"images/defaults/app-icon.png","promotionalText":null,"companyName":null,"emailReplyTo":"","privacyUrl":null,"termsUrl":null}},"categories":[{"id":43138,"slug":"uk-pharma-news","title":"UK News","color":"#444444","issueCount":0,"articleCount":85,"categoryGroupIds":[]},{"id":43139,"slug":"general-news","title":"General News","color":"#444444","issueCount":0,"articleCount":81,"categoryGroupIds":[]},{"id":43140,"slug":"approvals","title":"Approvals","color":"#444444","issueCount":0,"articleCount":162,"categoryGroupIds":[]},{"id":43141,"slug":"research-and-development","title":"R \u0026 D","color":"#444444","issueCount":0,"articleCount":174,"categoryGroupIds":[]},{"id":43143,"slug":"mergers-acquisitions","title":"Mergers \u0026 Acquisitions","color":"#444444","issueCount":0,"articleCount":74,"categoryGroupIds":[]},{"id":43144,"slug":"manufacturing-production","title":"Manufacturing","color":"#444444","issueCount":0,"articleCount":31,"categoryGroupIds":[]},{"id":43149,"slug":"clinical-trials","title":"Clinical Trials","color":"#444444","issueCount":0,"articleCount":41,"categoryGroupIds":[]},{"id":43145,"slug":"industry-insights","title":"Industry Insights","color":"#444444","issueCount":0,"articleCount":59,"categoryGroupIds":[]},{"id":43146,"slug":"appointments","title":"Appointments","color":"#444444","issueCount":0,"articleCount":94,"categoryGroupIds":[]},{"id":43147,"slug":"insider-interviews","title":"Interviews","color":"#444444","issueCount":0,"articleCount":9,"categoryGroupIds":[]},{"id":43148,"slug":"features","title":"Features","color":"#444444","issueCount":0,"articleCount":21,"categoryGroupIds":[]},{"id":43142,"slug":"industry-facts","title":"Industry Facts","color":"#444444","issueCount":0,"articleCount":24,"categoryGroupIds":[]}],"pwaSubscriptions":[],"categoryGroups":[],"slug":"european-commission-approves-combination-chemotherapy-for-treatm","article":{"id":262737,"slug":"european-commission-approves-combination-chemotherapy-for-treatm","issueId":52217,"categoryIds":[43139,43140,43138],"title":"European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated","description":"This month, Janssen-Cilag international, part of johnson \u0026 johnson (j\u0026j) has announced that the European Commission (EC) has approved a combined treatment of rybrevant (amivantamab) and chemotherapy (carboplatin and pemerexed) for the treatment of non-small cell lung cancer (nsclc) with an epidermal growth factor receptor (EGFR).","image":"https://cdn.magloft.com/pdf-import/1110/images/pages/pg-009.jpg","cover":"https://cdn.magloft.com/publication-14882/screenshots/articles/262737.jpg?ts=1725617944","date":1725577200000,"unlockType":"free","categories":[],"pdfPageId":"KdGQAljau6SM","visible":true,"showOnToc":true,"bookmark":false,"position":19,"mediaResources":[],"publicationId":14882,"pwaOptinId":null,"seoDescription":"This month, janssen-cilag international, part of johnson \u0026 johnson (j\u0026j) has announced that the european comission (ec) has approved a combined treatment o","classificationIds":[],"pwaSubscriptionIds":[],"source":"typeloft2","trending":false,"html":"\u003cpage-widget padding=\"16 0 24 0\"\u003e\u003cparagraph-widget padding=\"0 24 0 24\"\u003eApprovals\u003c/paragraph-widget\u003e\u003chorizontal-rule-widget padding=\"0 24 0 24\" color=\"#a31f29\"\u003e\u003c/horizontal-rule-widget\u003e\u003cheading-widget padding=\"0 24 16 24\" type=\"h2\"\u003e\u003cspan style=\"font-family: \u0026quot;Roboto Slab\u0026quot;;\" class=\"__bold\"\u003eEuropean Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients\u003c/span\u003e\u003c/heading-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003e\u003cspan class=\"__bold\" style=\"color: rgb(38,37,35)\"\u003eThis month, Janssen-Cilag International, part of Johnson \u0026amp; Johnson (J\u0026amp;J) has announced that the European Comission (EC) has approved a combined treatment of rybrevant (amivantamab) and chemotherapy (carboplatin and pemerexed) for the treatment of non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR). \u003c/span\u003e\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eJohn Reed, MD PhD, executive vice president, Innovative Medicine, R\u0026amp;D, Johnson \u0026amp; Johnson commented “Today’s FDA approval of chemotherapy-free rybrevant plus lazcluze in the first line is an incredible step towards our goal of altering the trajectory of lung cancer and reducing the impact of the world’s leading cause of cancer mortality.”\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eThe decision comes after the results of the phase 3 MARIPOSA study were announced. The study evaluated the safety profile and to the efficacy of amivantamab and chemotherapy in patients with locally-advanced or metastatic EGFR ex19del or L858R substitution NSCLC who had disease progression on or after treatment with osimertinib.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eAntonio Passaro, MD PhD, medical oncologist, Division of Thoracic Oncology at the European Institute of Oncology in Milan, Italy stated: “The addition of the bispecific antibody amivantamab to chemotherapy offers an important new treatment option for patients with EGFR ex19del or L858R mutations, progressing on or after osimertinib. In this setting, this combination set the new landmark for overall response rate and reduced the risk of disease progression or death by more than half compared to standard chemotherapy alone. It also demonstrated significant improvements in intracranial progression-free survival.”\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eThe trial met its primary endpoint, reducing the risk of disease progression or death by a significant 52% in comparison to chemotherapy alone. Additionally, amivantamab plus chemotherapy showed an objective response rate (ORR) of 64%, compared to 36 % with chemotherapy alone.\u003c/paragraph-widget\u003e\u003c/page-widget\u003e","keywordPhrase":"approve","articleAssets":[{"url":"https://cdn.magloft.com/reader/fonts/roboto-slab.css","extension":"css","contentType":"text/css"},{"url":"https://cdn.magloft.com/reader/fonts/open-sans.css","extension":"css","contentType":"text/css"}]},"publicationId":14882},"__N_SSG":true},"page":"/domains/[domain]/articles/[slug]","query":{"domain":"www.pharmafocus.com","slug":"european-commission-approves-combination-chemotherapy-for-treatm"},"buildId":"Kev2Q3R5ZPSsq42hjt5aX","isFallback":false,"gsp":true,"scriptLoader":[]}</script></body></html>